Register for email alerts and news feeds:
This journal | BMJ Group
rss
Thorax 2008;63:571-572; doi:10.1136/thx.2007.095042
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society.

EDITORIALS

Antagonism of tumour necrosis factor {alpha} in refractory asthma

Mike A Berry1, Ian D Pavord2

1 University of Birmingham, Edgbaston, Birmingham, UK
2 Institute for Lung Health, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK

Correspondence to:
Dr Mike A Berry, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; m.a.berry@bham.ac.uk

The first 150 words of the full text of this article appear below.

Asthma that is refractory to treatment with inhaled corticosteroids affects 5–10% of patients with asthma; it is an important health and economic problem in the UK and most industrialised nations. It is estimated that {euro}17.7 billion is spent on asthma healthcare per annum in Europe,1 of which a disproportionately large amount is attributed to patients with refractory asthma, on average six times more per patient compared with mild to moderate disease.2 Patients with this condition suffer considerable morbidity and mortality and they therefore represent an important unmet clinical need. The European Respiratory Society2 and the American Thoracic Society3 have identified research into the mechanisms and treatment of refractory asthma as a research priority.

Asthma can be apparently refractory to treatment because of poor treatment adherence or because symptoms are caused by comorbid conditions such as rhinitis, hyperventilation and bronchiectasis.4 However, a significant number of patients have genuinely severe disease. The . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Airwaves
Wisia Wedzicha
Thorax 2008 63: 571. [Extract] [Full Text] [PDF]

The role of a soluble TNF{alpha} receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial
J B Morjaria, A J Chauhan, K S Babu, R Polosa, D E Davies, and S T Holgate
Thorax 2008 63: 584-591. [Abstract] [Full Text] [PDF]

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Chest Medicine Jobs

Chest Medicine Jobs